An expanded access record providing TJ004309 and Atezolizumab in Cancer, sponsored by I-Mab Biopharma US Limited. No longer available at 3 sites in United States. Per ClinicalTrials.gov, last updated 2023-04-28.
Sponsored by I-Mab Biopharma US Limited · Expanded access
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This expanded access protocol was designed to provide TJ004309 in combination with atezolizumab to the remaining three patients with advanced or metastatic cancer who plan to continue with treatment.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
Browse Neoplasms studies →I-Mab Biopharma US Limited is the lead sponsor of 11 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Antibody to CD73
Humanized monoclonal antibody to PD-L1
Also known as: Tecentriq
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
I-Mab Biopharma US Limited